Denmark · Delayed Price · Currency is DKK H. Lundbeck Earnings Call Transcripts
Fiscal Year 2026
-
Record revenues and profitability were achieved in 2025, with strong growth in strategic brands and a robust pipeline. The board and executive team were re-elected, a new member with neuroscience expertise joined, and all proposals—including a 21% dividend increase—were approved.
Fiscal Year 2025
-
A focused neuroscience strategy, capital reallocation, and a simplified commercial model have driven strong growth, with VYEPTI and REXULTI as key assets. A diversified, innovation-driven pipeline and dynamic investment approach support upgraded financial guidance and long-term ambitions.
-
Double-digit revenue and profit growth in the first nine months of 2025 were driven by Vyepti and Rexulti, leading to upgraded full-year guidance. Strategic pipeline advances and commercial restructuring support long-term growth, despite FX and generic headwinds.
-
Strategic brands drove 21% growth and revenue rose 15% year-over-year, prompting upgraded guidance for both revenue and Adjusted EBITDA. Vyepti and Rexulti led performance, while pipeline and capital reallocation support long-term growth.
-
Q1 2025 saw 16% revenue growth and 24% rise in strategic brands, led by Vyepti and Rexulti. Full-year guidance was raised, reflecting strong demand, robust pipeline progress, and disciplined capital allocation, despite anticipated generic competition and portfolio erosion.
-
The AGM highlighted record financial results, a 36% dividend increase, and a strategic focus on rare neurological diseases through acquisitions and pipeline expansion. All board proposals were adopted, and key risks around R&D and market conditions were discussed with shareholders.
-
Significant progress was reported on growth, pipeline transformation, and financial discipline, with four late-stage assets and a robust commercial engine driving mid- and long-term outlook. Major acquisitions and focused R&D investment underpin a news-rich pipeline and sustainable growth strategy.
Fiscal Year 2024
-
2024 delivered record revenue and double-digit growth in strategic brands, with robust pipeline progress and a major acquisition. 2025 guidance anticipates continued strong growth, margin stability despite higher R&D, and resilience to competitive and generic pressures.
-
Revenue grew 13% year-over-year, led by 21% growth in strategic brands, with Vyepti and Rexulti as key drivers. The company raised its full-year guidance, reported strong cash flow, and is preparing for the Longboard acquisition, which will shift its net cash to net debt.
-
Focused innovation and capital reallocation are driving double-digit growth in strategic brands and transforming the pipeline, with four phase III programs expected by 2026. Financial guidance is raised, targeting mid-single-digit CAGR and a 30%-32% EBITDA margin, supported by the largest capital allocation program in company history.
-
The acquisition of Longboard Pharmaceuticals brings a de-risked, late-stage asset with breakthrough therapy designation for rare epilepsies, supporting long-term growth and a focused innovator strategy. The $2.5 billion deal is expected to close by year-end, with peak sales potential of $1.5–2 billion, mainly from the U.S.
-
Double-digit revenue growth and strong strategic brand performance led to raised 2024 guidance. Vyepti, Rexulti, and Brintellix/Trintellix drove results, with robust pipeline progress and a strengthened net cash position.